Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV


Key take-home messages
  • Oral PrEP (tenofovir disoproxil fumarate with emtricitabine) is highly protective against HIV acquisition across various populations and across different dosing schedules.
  • Open label and demonstration projects in both high- and low-income country settings have shown that oral tenofovir disoproxil fumarate with or without emtricitabine as PrEP can be delivered feasibly within existing health systems.
  • The protective efficacy of oral PrEP (tenofovir disoproxil fumarate with or without emtricitabine) for HIV prevention is highly dependent on adherence to the prescribed regimen.
  • Extremely rare cases of HIV infection with optimal adherence have been reported when transmission of drug-resistant mutations or atypical patterns of seroconversion have occurred.


The Ontario HIV Treatment Network: Rapid Response Service




  • Population(s)
    • Men who have sex with men
    • Women
    • Children or Youth (less than 18 years old)
    • People who use drugs
    • Heterosexual men
    • General HIV+ population
    • General HIV- population
  • Prevention
    • Biomedical interventions


Abstract/Full paper

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!